Design, synthesis, and evaluation of HIV-1 entry inhibitors based on broadly neutralizing antibody 447-52D and gp120 V3loop interactions

| GregoryGregory | 0 Comment
Design, synthesis, and evaluation of HIV-1 entry inhibitors based on broadly neutralizing antibody 447-52D and gp120 V3loop interactions
The third variable loop area (V3 loop) on gp120 performs an necessary position in mobile entry of HIV-1. Its interplay with the mobile CD4 and coreceptors is a crucial hallmark in facilitating the bridging by gp41 and subsequent fusion of membranes for switch of viral genetic materials. Additional, the virus phenotype determines the cell tropism by way of respective co- receptor binding.
Thus, coreceptor binding motif of envelope is taken into account to be a potent anti-viral drug goal for viral entry inhibition. Nonetheless, its excessive variability in sequence is the foremost hurdle for creating inhibitors concentrating on the area. On this examine, we have now used an in silico Digital Screening and “Fragment-based” methodology to design small molecules primarily based on the gp120 V3 loop interactions with a potent broadly neutralizing human monoclonal antibody, 447-52D.
From the in silico evaluation a potent scaffold, 1,3,5-triazine was recognized for additional growth. Derivatives of 1,3,5-triazine with particular useful teams have been designed and synthesized conserving the interplay with co-receptor intact. Lastly, preliminary analysis of molecules for HIV-1 inhibition on two completely different virus strains (clade C, clade B) yielded IC50 < 5.zero μM.
The method used to design molecules primarily based on broadly neutralizing antibody, was helpful for growth of goal particular potent antiviral brokers to forestall HIV entry. The examine reported promising inhibitors that might be additional developed and studied.

Cytokine antibody array-based evaluation of IL-37 therapy results in bronchial asthma

Bronchial asthma is pushed by group 2 innate lymphoid cells, antigen-specific CD4+ T helper sort 2 cells and their cytokines corresponding to interleukin (IL)-4, IL-5, IL-13. IL-37 is decreased in bronchial asthma and negatively associated to Th2 cytokines and different pro-inflammatory cytokines. Our examine confirmed that IL-37 degree in asthmatic peripheral blood mononuclear cells was decrease than in wholesome.
Additional, IL-37 was negatively correlated with exhaled nitric oxide, bronchial asthma management take a look at rating, atopy and rhinitis historical past in asthmatics. Then an OVA-induced bronchial asthma mice mannequin handled with rhIL-37 was established.
An antibody array was employed to uncover altered cytokines induced by IL-37 in mice lung tissue. 20 proteins differentially expressed after rhIL-37 therapy and 5 of them have been validated in asthmatic peripheral blood mononuclear cells. According to cytokine antibody array, CCL3, CCL4, CCL5 decreased after IL-37 administration. Whereas CXCL9 and CXCL13 have been no change. We concluded that IL-37 scale back asthmatic signs by inhibit pro-inflammatory cytokine corresponding to CCL3, CCL4, CCL5.

Editorial: The First Monoclonal Antibody Vaccine to Forestall Malaria Heralds a New Period of Malaria Vaccines to the Plasmodium falciparum Circumsporozoite Protein (PfCSP)

Malaria impacts greater than Three billion individuals in 95 nations, with an estimated mortality charge of 400,000 per 12 months. The feminine Anopheles spp mosquito mostly transmits malaria, and the primary burden of illness is because of Plasmodium falciparum. Essentially the most ample antigen on the sporozoite floor is the Plasmodium falciparum circumsporozoite protein (PfCSP).
PfCSP is required for parasite growth and attachment to host hepatocytes. The primary potential protein vaccine, RTS,S/ASO1, consists of a recombinant fusion antigen primarily based on PfCSP. Preliminary findings from a part Three trial of RTS,S/ASO1 have been promising however resulted in suggestions for additional analysis in large-scale trials. R21, a circumsporozoite protein-based vaccine, mixed with an adjuvant, Matrix-M (MM), was lately evaluated in a part 2 investigational examine in kids between 5-17 months of age in Burkina Faso.
The R21/MM candidate vaccine resulted in excessive titers of malaria-specific antibodies. On August 26, 2021, the findings from a part 1 trial on a brand new monoclonal antibody to PfCSP, CIS43LS, confirmed {that a} single dose of the CIS43LS monoclonal antibody resulted in safety towards malaria.
These new findings have implications for the seasonal management of malaria in endemic areas and a potential future position in public well being methods to get rid of malaria. This Editorial goals to supply the background to creating and evaluating the brand new malaria vaccines that focus on PfCSP, together with the primary monoclonal antibody vaccine to malaria.

Characterization and modulation of anti-αβTCR antibodies and their respective binding websites on the βTCR chain to complement engineered T cells

T cell engineering methods provide cures to sufferers and have entered scientific observe with chimeric antibody-based receptors; αβT cell receptor (αβTCR)-based methods are, nonetheless, lagging behind. To permit a extra speedy and profitable translation to profitable ideas additionally utilizing αβTCRs for engineering, incorporating a technique for the purification of genetically modified T cells, in addition to engineered T cell deletion after switch into sufferers, might be useful.
This might enable elevated efficacy, lowered potential unwanted side effects, and improved security of newly to-be-tested lead constructions. By characterizing the antigen-binding interface of a great manufacturing course of (GMP)-grade anti-αβTCR antibody, normally used for depletion of αβT cells from stem cell transplantation merchandise, we developed a method that permits for the purification of untouched αβTCR-engineered immune cells by altering 2 amino acids solely within the TCRβ chain fixed area of launched TCR chains.
Alternatively, we engineered an antibody that targets an prolonged mutated interface of 9 amino acids within the TCRβ chain fixed area and gives the chance to additional develop depletion methods of engineered immune cells.Design, synthesis, and evaluation of HIV-1 entry inhibitors based on broadly neutralizing antibody 447-52D and gp120 V3loop interactions

Monoclonal Antibodies From Anti-NMDA Receptor Encephalitis Affected person as a Software to Research Autoimmune Seizures

Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis manifests with precipitous cognitive decline, irregular actions, and extreme seizures that may be difficult to manage with typical anti-seizure drugs. We beforehand demonstrated that intracerebroventricular (i.c.v.) administration of cerebrospinal fluid from affected sufferers, or purified NMDA receptor antibodies from encephalitis sufferers to mice precipitated seizures, thereby confirming that antibodies are straight pathogenic for seizures.
Though completely different repertoires of anti-NMDA receptor antibodies might contribute to the distinct scientific manifestations in encephalitis sufferers, the position of particular antibodies within the expression of seizure, motor, and cognitive phenotypes stays unclear. Utilizing three completely different patient-derived monoclonal antibodies with distinct epitopes throughout the N-terminal area (NTD) of the NMDA receptor, we characterised the seizure burden, motor exercise and anxiety-related conduct in mice.
We discovered that steady administration of 5F5, 2G6 or 3C11 antibodies for two weeks precipitated seizures, as measured with steady EEG utilizing cortical screw electrodes. The seizure burden was comparable in all three antibody-treated teams. The seizures have been accompanied by elevated hippocampal C-C chemokine ligand 2 (CCL2) mRNA expression Three days after antibody infusion had stopped.

Anti-PD-L1
MBS684298-004mLConcentrate 0.04mL(Concentrate)
EUR 220

Anti-PD-L1
MBS684298-01mLConcentrate 0.1mL(Concentrate)
EUR 655

Anti-PD-L1
MBS684298-02mLConcentrate 0.2mL(Concentrate)
EUR 910

Anti-PD-L1
MBS684298-1mLRTU 1mL(RTU)
EUR 210

Anti-PD-L1
MBS684298-7mLRTU 7mL(RTU)
EUR 715

Anti-PD-L1 Antibody
A1454-100 each
EUR 405.6

Anti-PD-L1 Antibody
A1454-30T each
EUR 175.2

Anti-PD-L1 antibody
STJ180217 0.1 ml
EUR 336

Anti-PD-L1 antibody
STJ180383 0.1 ml
EUR 295.2

Anti-PD-L1 antibody
STJ190082 200 µl
EUR 236.4
Description: Unconjugated Mouse monoclonal to PD-L1 (AS1A7)

Anti-PD-L1 antibody
STJ130022 50 µl
EUR 385.2
Description: Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that suppresses immune system. PD-L1 is expressed in hematopoietic and nonhematopoietic cells including T cells and B cells and various types of tumor cells. PD-L1 binds to its receptor Programmed death 1 (PD1). During infection or inflammation, PD1PD-L1 interaction is important for preventing autoimmunity. In tumor microenvironments, PD1-PD-L1 interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human cancers. In recent years, PDL1 has become an important biomarker and immunotherapy target for many types of malignancies.

Anti-PD-L1 antibody
STJ130023 50 µl
EUR 385.2
Description: Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that suppresses immune system. PD-L1 is expressed in hematopoietic and nonhematopoietic cells including T cells and B cells and various types of tumor cells. PD-L1 binds to its receptor Programmed death 1 (PD1). During infection or inflammation, PD1PD-L1 interaction is important for preventing autoimmunity. In tumor microenvironments, PD1-PD-L1 interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human cancers. In recent years, PDL1 has become an important biomarker and immunotherapy target for many types of malignancies.

Anti-PD-L1 antibody
STJ130024 50 µl
EUR 385.2
Description: Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that suppresses immune system. PD-L1 is expressed in hematopoietic and nonhematopoietic cells including T cells and B cells and various types of tumor cells. PD-L1 binds to its receptor Programmed death 1 (PD1). During infection or inflammation, PD1PD-L1 interaction is important for preventing autoimmunity. In tumor microenvironments, PD1-PD-L1 interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human cancers. In recent years, PDL1 has become an important biomarker and immunotherapy target for many types of malignancies.

Anti-PD-L1 Antibody
34068 100ul
EUR 233

Anti-PD-L1 Antibody
MBS177526-01mg 0.1mg
EUR 450

Anti-PD-L1 Antibody
MBS177526-5x01mg 5x0.1mg
EUR 1870

Anti-PD-L1 Antibody
MBS178494-01mg 0.1mg
EUR 450

Anti-PD-L1 Antibody
MBS178494-5x01mg 5x0.1mg
EUR 1870

Rabbit anti PD-L1
E6TC00113 0.1mg
EUR 225
Description: Available in various conjugation types.

Rabbit anti PD-L1
MBS8576926-01mg 0.1mg
EUR 305

Rabbit anti PD-L1
MBS8576926-01mLAF405L 0.1mL(AF405L)
EUR 465

Rabbit anti PD-L1
MBS8576926-01mLAF405S 0.1mL(AF405S)
EUR 465

Rabbit anti PD-L1
MBS8576926-01mLAF610 0.1mL(AF610)
EUR 465

Rabbit anti PD-L1
MBS8576926-01mLAF635 0.1mL(AF635)
EUR 465

Anti-Canine PD-L1
34091 100ug
EUR 460

Anti-PD-L1 [Avelumab]
E2209924 1mg Ask for price
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

Avelumab (anti-PD-L1)
HY-108730A 1 mg
EUR 1060.62
Description: Avelumab (anti-PD-L1) is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity[1].

Anti-PD-L1 [Atezolizumab]
E2209925 1mg Ask for price
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

anti- PD-L1/CD274 antibody
FNab06280 100µg
EUR 606.3
Description: Antibody raised against PD-L1/CD274

anti- PD-L1/CD274 antibody
FNab06281 100µg
EUR 658.5
Description: Antibody raised against PD-L1/CD274

Anti- CD274 / PD-L1 Antibody
GWB-81DDFC 0.1 mg Ask for price

anti-PD-L1 VHH antibody
JOT0002-5 each Ask for price

anti-PD-L1 VHH antibody
JOT0002-5-1-100 100
EUR 148.12
Description: Primary VHH single domain antibody

anti-PD-L1 VHH antibody
JOT0002-5-1-1000 1000
EUR 880.6
Description: Primary VHH single domain antibody

anti-PD-L1 VHH antibody
JOT0002-5-1-2000 2000
EUR 1565.2
Description: Primary VHH single domain antibody

anti-PD-L1 VHH antibody
JOT0002-5-1-250 250
EUR 246.17
Description: Primary VHH single domain antibody

anti-PD-L1 VHH antibody
JOT0002-5-1-50 50
EUR 89.54
Description: Primary VHH single domain antibody

anti-PD-L1 VHH antibody
SB-JOT0002-5-1-100 100 (25 x 4)
EUR 148.4
Description: Primary VHH single domain antibody

anti-PD-L1 VHH antibody
SB-JOT0002-5-1-25 25
EUR 52.5
Description: Primary VHH single domain antibody

Anti-PD-L1 CD274 Antibody
A00109-1 0.1mg
EUR 449
Description: Boster Bio Anti-PD-L1 CD274 Antibody (Catalog # A00109-1). Tested in ELISA, WB, IHC-P, IF, Flow Cytometry applications. This antibody reacts with Human, Mouse, Rat.

Anti-PD-L1/CD274 Antibody
PB9994 100ug/vial
EUR 352.8

Anti-PD-L1/CD274 Antibody
PB9154 100ug/vial
EUR 352.8

Anti-PD-L1/CD274 Antibody
PA1851 100ug/vial
EUR 352.8

Anti-CD274 / PD-L1 antibody
STJ70646 100 µg
EUR 430.8

Anti-PD-L1/Cd274 Antibody
MBS1753278-01mg 0.1mg
EUR 450

Anti-PD-L1/Cd274 Antibody
MBS1753278-5x01mg 5x0.1mg
EUR 1870

Anti-Human PD-L1 Antibody
MBS378274-05mg 0.5mg
EUR 410

Anti-Human PD-L1 Antibody
MBS378274-5x05mg 5x0.5mg
EUR 1550

Anti-PD-L1/CD274 antibody
PAab06281 100ug
EUR 275

Anti-PD-L1/CD274 antibody
PAab06280 100 ug
EUR 426

Anti-PD-L1 Antibody (IHC411)
A1549-50 each
EUR 222

SensiStain Anti-PD-L1 Antibody
MBS4160486-05mL 0.5mL
EUR 320

SensiStain Anti-PD-L1 Antibody
MBS4160486-5x05mL 5x0.5mL
EUR 1180

Anti-PD-L1 Mouse mAb
GB12339 100 μL
EUR 100

Anti-PD-L1 Mouse mAb
GB14132 50 μL
EUR 100

Anti-PD-L1 Rabbit pAb
GB11339A 100 μL
EUR 100

Anti-PD-L1, PE-labeled
71128-1 50 µg
EUR 355
Description: R-Phycoerythrin-labeled anti-PD-L1 recombinant murine/human antibody recognizing the PD-1 binding region of human PD-L1. This antibody does not cross-react with mouse PD-L1, but does cross-react with monkey (M. fascicularis) PD-L1. It has not been tested with other species.

Anti-PD-L1, PE-labeled
71128-2 100 µg
EUR 510
Description: R-Phycoerythrin-labeled anti-PD-L1 recombinant murine/human antibody recognizing the PD-1 binding region of human PD-L1. This antibody does not cross-react with mouse PD-L1, but does cross-react with monkey (M. fascicularis) PD-L1. It has not been tested with other species.

Anti-PD-L1 [Avelumab] Humanized
MBS4751611-01mL 0.1mL
EUR 450

Anti-PD-L1 [Avelumab] Humanized
MBS4751611-5x01mL 5x0.1mL
EUR 1540

Anti-PD-L1 [Atezolizumab] Humanized
MBS4751612-01mL 0.1mL
EUR 450

Anti-PD-L1 [Atezolizumab] Humanized
MBS4751612-5x01mL 5x0.1mL
EUR 1540

PD-L1 / CD274 (GFP-tagged) - Mouse PD-L1 / CD274 antigen (PD-L1 / CD274)
MG203953 10 µg Ask for price

PD-L1 / CD274 (untagged) - Mouse PD-L1 / CD274 antigen (PD-L1 / CD274), (10ug)
MC201908 10 µg Ask for price

PD-L1
E8ET1701-41 100ul
EUR 275
Description: Available in various conjugation types.

PD-L1
MBS8534247-01mL 0.1mL
EUR 345

PD-L1
MBS8534247-01mLAF405L 0.1mL(AF405L)
EUR 565

PD-L1
MBS8534247-01mLAF405S 0.1mL(AF405S)
EUR 565

PD-L1
MBS8534247-01mLAF610 0.1mL(AF610)
EUR 565

PD-L1
MBS8534247-01mLAF635 0.1mL(AF635)
EUR 565

PD-L1
MBS191528-01mL 0.1mL
EUR 290

PD-L1
MBS191528-5x01mL 5x0.1mL
EUR 1295

PD-L1
MBS344033-01mLConcentrate 0.1mL(Concentrate)
EUR 175

PD-L1
MBS344033-1mLConcentrate 1mL(Concentrate)
EUR 315

PD-L1
MBS344033-5x1mLConcentrate 5x1mL(Concentrate)
EUR 1165

PD-L1
MBS344033-7mLRTU 7mL(RTU)
EUR 220

PD-L1
MBS495604-1mL 1mL
EUR 1145

PD-L1
MBS495604-5x1mL 5x1mL
EUR 5010

PD-L1 Antibody
4059-002mg 0.02 mg
EUR 206.18
Description: PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, PD-L1 modulates the activation threshold of T-cells and limits T-cell effector response (1). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (2,3). Through a yet unknown activating receptor, it may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (4).

PD-L1 Antibody
4059-01mg 0.1 mg
EUR 523.7
Description: PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, PD-L1 modulates the activation threshold of T-cells and limits T-cell effector response (1). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (2,3). Through a yet unknown activating receptor, it may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (4).

PD-L1 Antibody
49251 100ul
EUR 499

PD-L1 Antibody
49251-100ul 100ul
EUR 399.6

PD-L1 Antibody
49251-50ul 50ul
EUR 286.8

PD-L1 Antibody
DF6526-100ul 100ul
EUR 280

PD-L1 Antibody
DF6526-200ul 200ul
EUR 350

PD-L1 Antibody
P1013-01m 0.1m
EUR 224.4

PD-L1 Antibody
P1013-1ml 1ml
EUR 807.6

PD-L1 Antibody
R33263-100UG 100 ug
EUR 339.15
Description: Additional name(s) for this target protein: Programmed cell death 1 ligand 1; CD274

PD-L1 Antibody
R31573 100 ug
EUR 356.15
Description: Programmed death-ligand 1, also known as CD274 or B7-H1 is a protein that in humans is encoded by the CD274 gene. It is a 33-70kDa type 1 transmembrane protein that has been speculated to play a major role in suppressing the immune system during particular events such as pregnancy, tissue allografts, autoimmune disease and other disease states such as hepatitis. Upregulation on tumor MDCs downregulates T-cell immunity and PD-L1 blockade may represent an approach for cancer immunotherapy. It can provide positive costimulatory signals for innate and adaptive immunity and for protection against intracellular bacterial infection. It has been found that PD1/PDL1 pathway may be a good target for restoring antitumor immunity in ovarian cancer.

PD-L1 Antibody
MBS346028-001mL 0.01mL
EUR 205

PD-L1 Antibody
MBS346028-01mL 0.1mL
EUR 335

PD-L1 Antibody
MBS346028-02mL 0.2mL
EUR 480

PD-L1 Antibody
MBS346028-05mL 0.5mL
EUR 845

PD-L1 Antibody
MBS346028-1mL 1mL
EUR 1285

PD-L1 Antibody
MBS5400772-01mg 0.1mg
EUR 445

PD-L1 Antibody
MBS5400772-5x01mg 5x0.1mg
EUR 1855

PD-L1 Antibody
MBS9436868-INQUIRE INQUIRE Ask for price

PD-L1 Antibody
MBS9436000-005mL 0.05mL
EUR 325

PD-L1 Antibody
MBS9436000-01mL 0.1mL
EUR 435

PD-L1 Antibody
MBS9436000-5x01mL 5x0.1mL
EUR 1810

Anti-PD-L1/B7-H1 Antibody
MBS178585-01mg 0.1mg
EUR 450

Anti-PD-L1/B7-H1 Antibody
MBS178585-5x01mg 5x0.1mg
EUR 1870

Anti-PD-L1 Antibody [JJ08-95]
ET1701-41 100ul
EUR 231
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T cell proliferation, cytokine production, differentiation of effector T cells, and the induction of Bcl-x, a promoter of T cell survival. Conversely, engagement of CTLA4 by B7-1 or B7-2 may inhibit proliferation and IL-2 production. Pdcd-1L1 (programmed cell death ligand-1), also known as B7-H1 or PD-L1, is 290 amino acid type I transmembrane protein which is 20% and 15% identical to B7-1 and B7-2, respectively. Pdcd-1L2 has immunoglobulin V-like and C-like domains and a 30 amino acid cytoplasmic tail. It does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of Pdcd-1L1 co-stimulation. The gene which encodes Pdcd-1L1 maps to human chromosome 9p24. Pdcd-1L2 (programmed cell death ligand-2) is a 73 amino acid protein which contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The gene which encodes Pdcd-1L2 maps to human chromosome 9p24.2. The constitutive expression of Pdcd-1L1 and Pdcd-1L2 on paren-chymal cells of heart, lung and kidney suggests that the Pdcd-1-Pdcd-L system could provide unique negative signaling to help prevent autoimmune disease.

Anti-PD-L1 Antibody [JJ08-95]
ET1701-41TR 20ul
EUR 64.35
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T cell proliferation, cytokine production, differentiation of effector T cells, and the induction of Bcl-x, a promoter of T cell survival. Conversely, engagement of CTLA4 by B7-1 or B7-2 may inhibit proliferation and IL-2 production. Pdcd-1L1 (programmed cell death ligand-1), also known as B7-H1 or PD-L1, is 290 amino acid type I transmembrane protein which is 20% and 15% identical to B7-1 and B7-2, respectively. Pdcd-1L2 has immunoglobulin V-like and C-like domains and a 30 amino acid cytoplasmic tail. It does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of Pdcd-1L1 co-stimulation. The gene which encodes Pdcd-1L1 maps to human chromosome 9p24. Pdcd-1L2 (programmed cell death ligand-2) is a 73 amino acid protein which contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The gene which encodes Pdcd-1L2 maps to human chromosome 9p24.2. The constitutive expression of Pdcd-1L1 and Pdcd-1L2 on paren-chymal cells of heart, lung and kidney suggests that the Pdcd-1-Pdcd-L system could provide unique negative signaling to help prevent autoimmune disease.

Anti-PD-L1 Antibody [PD01-02]
HA721176 100ul
EUR 231
Description: PD-L1 (programmed-death ligand 1; CD274), is a transmembrane protein constitutionally expressed on a variety of cell types, including antigen presenting cells (dendritic cells and histiocytes) and some non-lymphoid tissues (heart and lung). Binding of PD-L1 to PD-1 (programmed-death 1; CD279) expressed by activated T-cells, inhibits their function, causing negative feedback control of immunological reactions, thus impeding inflammation and autoimmunity. Tumour cells may express PD-L1, which binds to PD-1 allowing cancer cells to evade the attack of T-cells. Blockade of the PD-1/PD-L1 pathway has now shown useful in therapy of multiple cancer types, causing durable tumour regressions in a substantial proportion of otherwise treatment refractory cases of melanoma, and carcinomas of e.g., lung, kidney, and urinary tract. Patients without tumour PD-L1 expression can also derive benefit from blocking agents (studies across multiple cancer types demonstrate a pooled response rate of 48% in patients with PD-L1-positive tumours compared to 15% in PD-L1-negative tumours). Tonsil and placenta can be used as positive and negative tissue controls. However, tonsil is found to be superior to placenta, as tonsil displayes a range of PD-L1 expression levels. Tonsil displayes the following reaction pattern: No staining reaction in the vast majority of lymphocytes including mantle zone and germinal centre B-cells, no staining reaction in superficial epithelial cells, a weak to moderate, typically punctuated membranous staining reaction of the majority of germinal centre macrophages and finally a moderate to strong staining reaction of the majority of epithelial crypt cells.

ExoQuali™ Anti- PD-L1 Antibody
CEA-025L-100ug 100ug Ask for price

ExoQuali™ Anti- PD-L1 Antibody
CEA-025L-50ug 50ug Ask for price

Goat anti-CD274 / PD-L1 Antibody
dAP-0602 50ug
EUR 264.6

Goat anti-CD274/PD-L1 Antibody
MBS421103-01mg 0.1mg
EUR 400

Goat anti-CD274/PD-L1 Antibody
MBS421103-5x01mg 5x0.1mg
EUR 1660

SensiStain™ Anti-PD-L1 Antibody
HY000271 0.1 ml
EUR 188.5

SensiStain™ Anti-PD-L1 Antibody
HY500011 0.1 ml
EUR 188.5

Anti-PD-L1, Rabbit clonal antibody
MBS684299-004mLConcentrate 0.04mL(Concentrate)
EUR 215

Anti-PD-L1, Rabbit clonal antibody
MBS684299-01mLConcentrate 0.1mL(Concentrate)
EUR 655

Anti-PD-L1, Rabbit clonal antibody
MBS684299-02mLConcentrate 0.2mL(Concentrate)
EUR 910

Anti-PD-L1, Rabbit clonal antibody
MBS684299-1mLRTU 1mL(RTU)
EUR 205

Anti-PD-L1, Rabbit clonal antibody
MBS684299-7mLRTU 7mL(RTU)
EUR 715

Mouse anti PD-L1 Monoclonal Antibody
MBS460824-01mg 0.1mg
EUR 320

Mouse anti PD-L1 Monoclonal Antibody
MBS460824-5x01mg 5x0.1mg
EUR 1390

Mouse anti PD-L1 Monoclonal Antibody
MBS460825-01mg 0.1mg
EUR 320

Mouse anti PD-L1 Monoclonal Antibody
MBS460825-5x01mg 5x0.1mg
EUR 1390

Mouse anti PD-L1 Monoclonal Antibody
MBS460836-01mg 0.1mg
EUR 320

Mouse anti PD-L1 Monoclonal Antibody
MBS460836-5x01mg 5x0.1mg
EUR 1390

Mouse anti PD-L1 Monoclonal Antibody
MBS460838-01mg 0.1mg
EUR 320

Mouse anti PD-L1 Monoclonal Antibody
MBS460838-5x01mg 5x0.1mg
EUR 1390

Mouse monoclona Anti-PD-L1 Antibody
TA355105 100 µg Ask for price

Anti-PD-L1 Antibody, Mouse Monoclonal
MBS8100731-002mL 0.02mL
EUR 155

Anti-PD-L1 Antibody, Mouse Monoclonal
MBS8100731-01mL 0.1mL
EUR 300

Anti-PD-L1 Antibody, Mouse Monoclonal
MBS8100731-5x01mL 5x0.1mL
EUR 1200

Anti-PD-L1 Antibody, Mouse Monoclonal
MBS8100732-01mL 0.1mL
EUR 300

Anti-PD-L1 Antibody, Mouse Monoclonal
MBS8100732-5x01mL 5x0.1mL
EUR 1200

Anti-PD-L1 Antibody, Mouse Monoclonal
MBS8100733-002mL 0.02mL
EUR 175

Anti-PD-L1 Antibody, Mouse Monoclonal
MBS8100733-01mL 0.1mL
EUR 320

Anti-PD-L1 Antibody, Mouse Monoclonal
MBS8100733-5x01mL 5x0.1mL
EUR 1300

Anti-PD-L1 Antibody, Mouse Monoclonal
MBS8100734-01mL 0.1mL
EUR 300

Anti-PD-L1 Antibody, Mouse Monoclonal
MBS8100734-5x01mL 5x0.1mL
EUR 1200

Anti-PD-L1 Antibody, Mouse Monoclonal
MBS8100738-002mL 0.02mL
EUR 175

Anti-PD-L1 Antibody, Mouse Monoclonal
MBS8100738-01mL 0.1mL
EUR 320

Anti-PD-L1 Antibody, Mouse Monoclonal
MBS8100738-5x01mL 5x0.1mL
EUR 1300

Anti-PD-L1 Antibody, Mouse Monoclonal
MBS8100740-01mL 0.1mL
EUR 300

Anti-PD-L1 Antibody, Mouse Monoclonal
MBS8100740-5x01mL 5x0.1mL
EUR 1200

Anti-PD-L1 Antibody, Rabbit Polyclonal
MBS8110760-01mL 0.1mL
EUR 300

Anti-PD-L1 Antibody, Rabbit Polyclonal
MBS8110760-5x01mL 5x0.1mL
EUR 1200

Anti-PD-L1 Antibody, Rabbit Polyclonal
MBS8110761-01mL 0.1mL
EUR 300

Anti-PD-L1 Antibody, Rabbit Polyclonal
MBS8110761-5x01mL 5x0.1mL
EUR 1200

Anti-PD-L1 Antibody, Rabbit Polyclonal
MBS8110762-002mL 0.02mL
EUR 155

Anti-PD-L1 Antibody, Rabbit Polyclonal
MBS8110762-01mL 0.1mL
EUR 300

Anti-PD-L1 Antibody, Rabbit Polyclonal
MBS8110762-5x01mL 5x0.1mL
EUR 1200

Anti-PD-L1 Antibody, Rabbit Polyclonal
MBS8100752-01mL 0.1mL
EUR 300

Anti-PD-L1 Antibody, Rabbit Polyclonal
MBS8100752-5x01mL 5x0.1mL
EUR 1200

Anti-PD-L1 Antibody, Rabbit Polyclonal
MBS8100753-01mL 0.1mL
EUR 340

Anti-PD-L1 Antibody, Rabbit Polyclonal
MBS8100753-5x01mL 5x0.1mL
EUR 1375

Anti-PD-L1 Antibody, Rabbit Polyclonal
MBS8100755-01mL 0.1mL
EUR 340

Anti-PD-L1 Antibody, Rabbit Polyclonal
MBS8100755-5x01mL 5x0.1mL
EUR 1375

Anti-PD-L1 Antibody, Rabbit Polyclonal
MBS8100756-002mL 0.02mL
EUR 155

Anti-PD-L1 Antibody, Rabbit Polyclonal
MBS8100756-01mL 0.1mL
EUR 300

Anti-PD-L1 Antibody, Rabbit Polyclonal
MBS8100756-5x01mL 5x0.1mL
EUR 1200

Anti-PD-L1 Antibody, Rabbit Polyclonal
MBS8113274-01mL 0.1mL
EUR 300

Anti-PD-L1 Antibody, Rabbit Polyclonal
MBS8113274-5x01mL 5x0.1mL
EUR 1200

Anti-PD-L1 (CD274) Neutralizing Antibody
71213 100 µg
EUR 505
Description: Neutralizing recombinant chimeric murine/human monoclonal antibody recognizing the extracellular domain of PD-L1 and blocking the binding of PD-L1 to PD-1. This antibody has been shown to cross-react with mouse PD-L1. No other species have been tested.

Anti-CD274 / PD-L1, Biotinylated antibody
STJ73200 100 µg
EUR 430.8

PD-L1 / CD274 (Myc-DDK-tagged) - Mouse PD-L1 / CD274 antigen (PD-L1 / CD274)
MR203953 10 µg Ask for price

Anti-PD-L1 (Atezolizumab), humanized Antibody
A1305-100 each
EUR 601.2

SensiStain Anti-Recombinant PD-L1 Antibody
MBS4160507-05mL 0.5mL
EUR 320

SensiStain Anti-Recombinant PD-L1 Antibody
MBS4160507-5x05mL 5x0.5mL
EUR 1180

human anti-human PD-L1 mAb
E409C28-h100 100μL
EUR 395
Description: Available in various conjugation types.

mouse anti-human PD-L1 mAb
E409C28-m100 100μL
EUR 395
Description: Available in various conjugation types.

human anti-human PD-L1 mAb
E4A09L05 50ug
EUR 255
Description: Available in various conjugation types.

Human anti-Human PD-L1 mAb
MBS8576837-005mg 0.05mg
EUR 325

Human anti-Human PD-L1 mAb
MBS8576837-01mLAF405L 0.1mL(AF405L)
EUR 565

Human anti-Human PD-L1 mAb
MBS8576837-01mLAF405S 0.1mL(AF405S)
EUR 565

Human anti-Human PD-L1 mAb
MBS8576837-01mLAF610 0.1mL(AF610)
EUR 565

Human anti-Human PD-L1 mAb
MBS8576837-01mLAF635 0.1mL(AF635)
EUR 565

Mouse anti-Human PD-L1 mAb
MBS8576838-005mg 0.05mg
EUR 325

Mouse anti-Human PD-L1 mAb
MBS8576838-01mLAF405L 0.1mL(AF405L)
EUR 565

Mouse anti-Human PD-L1 mAb
MBS8576838-01mLAF405S 0.1mL(AF405S)
EUR 565

Mouse anti-Human PD-L1 mAb
MBS8576838-01mLAF610 0.1mL(AF610)
EUR 565

Mouse anti-Human PD-L1 mAb
MBS8576838-01mLAF635 0.1mL(AF635)
EUR 565

Anti-PD-L1 [332M7], Human IgG1
MBS488961-02mg 0.2mg
EUR 520

Anti-PD-L1 [332M7], Human IgG1
MBS488961-5x02mg 5x0.2mg
EUR 2160

Anti-PD-L1 [332M7], Rabbit IgG
MBS488962-02mg 0.2mg
EUR 520

Anti-PD-L1 [332M7], Rabbit IgG
MBS488962-5x02mg 5x0.2mg
EUR 2160

Anti-PD-L1-mIgG1e3 InvivoFit™
pdl1-mab15-1 1 mg
EUR 353.85

Anti-PD-L1-mIgG1e3 InvivoFit™
pdl1-mab15-10 10 mg
EUR 2285.85

Anti-PD-L1-mIgG1e3 InvivoFit™
pdl1-mab15-50 50 mg
EUR 5208

PD-L1 / CD274 (untagged)-Human PD-L1 / CD274 molecule (PD-L1 / CD274)
SC115168 10 µg Ask for price

PD-L1 / CD274 (GFP-tagged) - Human PD-L1 / CD274 molecule (PD-L1 / CD274)
RG213071 10 µg Ask for price

Anti-Human B7-H1/PD-L1 Antibody
102-P23 100 µg
EUR 245.7
Description: Human B7 homolog 1 (B7H1), also called programmed death ligand 1 (PDL1) and programmed cell death 1 ligand 1 (PDCD1L1), is a member of the growing B7 family of immune proteins that provide signals for both stimulating and inhibiting T cell activation. Other family members include B71, B72, B7H2, PDL2 and B7H3. B7 proteins are members of the immunoglobulin (Ig) superfamily, their extracellular domains contain 2 Ig-like domains and all members have short cytoplasmic domains. Among the family members, they share about 20 25% amino acid identity. Human and mouse B7H1 share approximately 70% amino acid sequence identity. B7H1 has been identified as one of two ligands for programmed death1 (PD1), a member of the CD28 family of immunoreceptors. The B7H1 gene encodes a 290 amino acid (aa) type I membrane precursor protein with a putative 18 aa signal peptide, a 221 aa extracellular domain, a 21 aa transmembrane region, and a 31 aa cytoplasmic domain. Human B7H1 is constitutively expressed in several organs such as heart, skeletal muscle, placenta and lung, and in lower amounts in thymus, spleen, kidney and liver. B7H1 expression is upregulated in a small fraction of activated T and B cells and a much larger fraction of activated monocytes. B7H1 expression is also induced in dendritic cells and keratinocytes after IFNγ stimulation. Interaction of B7H1 with PD1 results in inhibition of TCR-mediated proliferation and cytokine production. The B7H1: PD1 pathway is involved in the negative regulation of some immune responses and may play an important role in the regulation of peripheral tolerance.

Anti-PD-L1/B7-H1/CD274 Antibody
A00109 100ug/vial
EUR 352.8

PE Anti-Mouse CD274/PD-L1 Antibody
DL21657F-20Tests 20Tests
EUR 152
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production.

PE Anti-Mouse CD274/PD-L1 Antibody
DL21657F-50Tests 50Tests
EUR 207.5
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production.

PE Anti-Mouse CD274/PD-L1 Antibody
DL21660F-25ug 25μg
EUR 200
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production.

PE Anti-Mouse CD274/PD-L1 Antibody
DL21660F-50ug 50μg
EUR 282.5
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production.

PE Anti-Human CD274/PD-L1 Antibody
DL21667F-20Tests 20Tests
EUR 192.5
Description: CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells.

PE Anti-Human CD274/PD-L1 Antibody
DL21667F-50Tests 50Tests
EUR 267.5
Description: CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells.

PE Anti-Mouse CD274/PD-L1 Antibody
RD21657F-100Tests 100Tests
EUR 112.5
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production.

PE Anti-Mouse CD274/PD-L1 Antibody
RD21657F-100Testsx2 100Testsx2
EUR 172.5
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production.

PE Anti-Mouse CD274/PD-L1 Antibody
RD21657F-50Tests 50Tests
EUR 67.5
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production.

PE Anti-Mouse CD274/PD-L1 Antibody
RD21660F-100ug 100μg
EUR 225
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production.
Antibodies didn’t have an effect on the motor efficiency or anxiousness scores in mice. These findings counsel that neuronal antibodies concentrating on completely different epitopes throughout the NMDA receptor could end in the same seizure phenotype.
Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Post

Effect of Qiangji Jianli decoction on mitochondrial respiratory chain activity and expression of mitochondrial fusion and fission proteins in myasthenia gravis rats.

Effect of Qiangji Jianli decoction on mitochondrial respiratory chain activity and expression of mitochondrial fusion and fission proteins in myasthenia gravis rats.Effect of Qiangji Jianli decoction on mitochondrial respiratory chain activity and expression of mitochondrial fusion and fission proteins in myasthenia gravis rats.

Myasthenia gravis (MG) is an autoimmune neuromuscular illness characterised by the manufacturing of antibodies in opposition to acetylcholine receptors (AChRs). Qiangji Jianli (QJJL) decoction is an efficient conventional Chinese language medication (TCM)

READ MOREREAD MORE